Formulation development and evaluation of vonoprazon incorporated nanosuspension

The development and evaluation of a vonoprazan-loaded nanosuspension represent a promising formulation strategy to overcome the solubility and bioavailability limitations of this potassium-competitive acid blocker (P-CAB). Vonoprazan exhibits superior and rapid acid suppression efficacy compared to conventional proton pump inhibitors (PPIs), which has been demonstrated clinically in erosive esophagitis and acid-related disorders [1][2][3]. However, its poor aqueous solubility (~0.045 mg/mL) constrains oral bioavailability, which nanosuspensions can effectively address.Formulation DevelopmentNanosuspensions are submicron colloidal dispersions of drug particles stabilized by surfactants or polymers. They leverage particle size reduction to nanoscale dimensions (<1 µm) to increase surface area, thereby enhancing dissolution rate as described by the Noyes–Whitney equation:

$$\frac{dC}{dt} = \frac{\text{DA}}{h}(C_s - C)$$

where $dC/dt$ is the dissolution rate, $D$ is diffusion coefficient, $A$ is surface area, $h$ is diffusion layer thickness, $C_s$ is saturation solubility, and $C$ is concentration in bulk solution.

Additionally, according to the Ostwald-Freundlich equation, reducing particle size increases saturation solubility:

$$\ln\frac{C_{r}}{C_{\infty}} = \frac{2\gamma V_m}{\text{r RT}}$$

where $C_r$ is solubility for particle radius $r$, $C_{\infty}$ is solubility of bulk material, $\gamma$ is interfacial tension, $V_m$ molar volume, $R$ gas constant, and $T$ temperature.

The preparation of vonoprazan nanosuspension typically involves antisolvent precipitation combined with high-speed homogenization and probe sonication. The approach involves dissolving vonoprazan in a good solvent (e.g., ethanol) and rapidly mixing into an aqueous antisolvent phase containing stabilizers such as Poloxamer 188 and polyvinyl alcohol (PVA), which adsorb onto particle surfaces, preventing aggregation and facilitating stable nanosuspension formation [4][5].

Optimization through Design of Experiment (DoE) methods like Box–Behnken design enables fine-tuning critical variables such as drug-to-stabilizer ratio, sonication time, and homogenization speed to achieve desirable particle size, low polydispersity index (PDI), and suitable zeta potential for stability [6].Evaluation and CharacterizationKey characterization parameters include:

• Particle Size and PDI: Dynamic light scattering (DLS) typically shows nanosuspensions of approximately 185–370 nm particle size with PDI <0.2, indicating uniform size distribution [4][7].

• Zeta Potential: Values around -20 to -30 mV indicate good electrostatic stabilization, reducing particle agglomeration in suspension [4].

• Crystallinity: Differential scanning calorimetry (DSC) and X-ray diffraction (XRD) often reveal a reduction in crystallinity or partial drug amorphization, which further facilitates enhanced dissolution [5][7].

• Morphology: Transmission electron microscopy (TEM) or scanning electron microscopy (SEM) confirms nanoscale particle sizes and shapes, e.g., spherical or rod-shaped morphology [6].

• Drug Content and Entrapment Efficiency: High drug loading (~98%) and entrapment efficiency (>90%) confirm minimal drug loss during processing [8].

• In Vitro Dissolution: Nanosuspensions significantly enhance dissolution rate; for vonoprazan, >90% release within 30 minutes in simulated gastric fluid (pH 1.2) compared to 30% release from the pure drug due to increased surface area and solubility [7].

• Stability: Physical stability is indicated by negligible changes in particle size and drug content over at least 3 months under refrigeration and room temperature conditions [5].

Potential Impact on Bioavailability and Therapeutic EfficacyNanosuspension formulation enhances the oral delivery of poorly water-soluble drugs by increasing dissolution and gastrointestinal absorption. For vonoprazan, improving bioavailability could potentiate its rapid and sustained acid suppression effects already demonstrated clinically, which are superior or non-inferior to lansoprazole and other PPIs in healing erosive esophagitis and maintaining remission [1][3]. Enhanced bioavailability can:

• Achieve therapeutic plasma concentrations faster, as vonoprazan is known for early onset action within hours [2].

• Potentially reduce dose or dosing frequency, improving patient compliance and safety.

• Mitigate possible inter-subject variability due to dissolution-limited absorption.

Pharmacokinetic interactions need consideration; for example, co-administration with voriconazole significantly alters vonoprazan metabolism and elimination, indicating that nanosuspension formulations should be evaluated in pharmacokinetic studies to detect any alteration in drug exposure or interactions [9].Comparison with Other Nanosuspension ApplicationsInsights from other nanosuspension formulations confirm their advantages:

• Carvedilol nasal nanosuspensions improved bioavailability by over 2.5 times compared to oral dosing [4].

• Atovaquone nanosuspension increased area under curve (AUC) by approximately 3–4 fold in vivo, demonstrating clinical relevance of nanosizing [7].

• Glimepiride nanosuspensions exhibited enhanced antihyperglycemic activity due to improved pharmacokinetics [5].

Such precedents underscore the feasibility and benefit of adapting nanosuspension technology for vonoprazan.Conclusion and Future DirectionsThe formulation of vonoprazan nanosuspension via antisolvent precipitation combined with homogenization and sonication, stabilized by agents like Poloxamer 188 and PVA, produces nanosized, stable particles exhibiting increased dissolution rate and potentially enhanced bioavailability. Physicochemical characterizations confirm particle size reduction and partial amorphization as critical factors for solubility enhancement. Stability studies support the formulation’s feasibility for further development.

To decisively establish the clinical benefit of vonoprazan nanosuspension, comprehensive in vivo pharmacokinetic and pharmacodynamic studies are warranted, followed by safety and efficacy evaluations. These studies should also consider potential drug-drug interactions given vonoprazan’s metabolism and reported interactions, such as with voriconazole [9]. The nanosuspension platform represents a valuable nanotechnological advancement for optimizing vonoprazan therapy in acid-related diseases.

---

References used: [1][2][3][4][5][6][7][8][9]